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In this study, we analysed gene amplification, RNA expression and protein expression of the c-myc gene on archival tissue specimens
of high-grade human breast cancer, using fluorescent in situ hybridisation (FISH), nonradioactive in situ hybridisation and
immunohistochemistry. The specific question that we addressed was whether expression of c-Myc mRNA and protein were
correlated with its gene copy amplification, as determined by FISH. Although c-Myc is one of the most commonly amplified
oncogenes in human breast cancer, few studies have utilised in situ approaches to directly analyse the gene copy amplification, RNA
transcription and protein expression on human breast tumour tissue sections. We now report that by using the sensitive FISH
technique, a high proportion (70%) of high-grade breast carcinoma were amplified for the c-myc gene, irrespective of status of the
oestrogen receptor. However, the level of amplification was low, ranging between one and four copies of gene gains, and the majority
(84%) of the cases with this gene amplification gained only one to two copies. Approximately 92% of the cases were positive for c-
myc RNA transcription, and essentially all demonstrated c-myc protein expression. In fact, a wide range of expression levels were
detected. Statistically significant correlations were identified among the gene amplification indices, the RNA expression scores and
protein expression scores. c-myc gene amplification, as detected by FISH, was significantly associated with expression of its mRNA, as
measured by the intensity of in situ hybridisation in invasive cells (P¼0.0067), and by the percentage of invasive cells positive for
mRNA expression (P¼0.0006). c-myc gene amplification was also correlated with the percentage of tumour cells which expressed
high levels of its protein, as detected by immunohistochemistry in invasive cells (P¼0.0016). Thus, although multiple mechanisms are
known to regulate normal and aberrent expression of c-myc, in this study, where in situ methodologies were used to evaluate high-
grade human breast cancers, gene amplification of c-myc appears to play a key role in regulating expression of its mRNA and protein.
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The c-myc oncogene has been shown to be amplified and/or
overexpressed in many types of human cancer (Marcu et al, 1992;
Nass and Dickson, 1997; Nesbit et al, 1999; Liao and Dickson,
2000). Numerous experiments in vivo have also causally linked
aberrant expression of this gene to the development and
progression of cancer in different body sites (Marcu et al, 1992;
Nass and Dickson, 1997; Nesbit et al, 1999; Liao and Dickson,
2000). However, several critical issues regarding the significance of
c-myc in human cancer still remain obscure. First, even for a given
type of malignancy, the frequencies of the alterations of c-myc at
the cytogenetic and expression levels vary greatly from one report
to another (Liao and Dickson, 2000). For instance, the frequencies
of its amplification, mRNA and protein overexpression in breast
cancer vary between 1–94, 22–95 and roughly 50–100%,
respectively, among different reports (Liao and Dickson, 2000).
Thus, it is still unclear to what extent this gene is altered at the
cytogenetic level and at different expression levels in breast
carcinoma.
One controversial issue pertains to the prognostic value of c-myc
gene alterations in cancer. The central role of c-Myc protein in
accelerating cell proliferation, documented by many early studies,
has led to a general concept for many types of cancer that
amplification or overexpression of this gene may be associated
with a more aggressive tumour and a poorer patient survival
(Berns et al, 1992; Marcu et al, 1992; Sato et al, 1995; Nass and
Dickson, 1997; Nesbit et al, 1999; Visca et al, 1999; Liao and
Dickson, 2000). However, many reports have shown an opposite
correlation (Sikora et al, 1985, 1987; Watson et al, 1986; Polacarz
et al, 1989; Voravud et al, 1989; Williams et al, 1990; Melhem et al,
1992; Pietilainen et al, 1995; Diebold et al, 1996; Smith and Goh,
1996; Augenlich et al, 1997; Bieche et al, 1999), while other studies
do not support either of these conclusions. For instance, gene
amplification or overexpression of c-Myc protein has also been
shown to associate with a better tumour differentiation or a better
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spatient survival for cancer of the testis, ovary, bile ducts, colon and
breast (Sikora et al, 1985, 1987; Watson et al, 1986; Polacarz et al,
1989; Voravud et al, 1989; Williams et al, 1990; Melhem et al, 1992;
Pietilainen et al, 1995; Diebold et al, 1996; Smith and Goh, 1996;
Augenlich et al, 1997; Bieche et al, 1999). This controversy does
not appear to be related completely to the cancer type, since both
positive (Berns et al, 1992; Visca et al, 1999) and negative
(Williams et al, 1990; Melhem et al, 1992; Pietilainen et al, 1995;
Smith and Goh, 1996; Augenlich et al, 1997; Bieche et al, 1999)
correlations have been reported for colon cancer and breast
cancer. More interestingly, c-Myc overexpression has been shown
to predict a poorer prognosis for cutaneous melanoma, but a
favourable outcome for uveal melanoma (Grover et al, 1997; Chana
et al, 1998a, b, 1999; Grover et al, 1999). These data indicate
different roles of c-Myc, even in the same type of tumour, perhaps
depending upon different tissue microenvironments.
Another controversial issue concerns the nuclear–cytoplasmic
localisation of c-Myc. Studies of neoplasms of the colon, testis,
ovary and liver have shown that predominantly nuclear localisa-
tion of c-Myc tends to occur in benign lesions, while cytoplasmic
localisation tends to occur in more malignant tumours (Sikora
et al, 1985; Sundaresan et al, 1987; Melhem et al, 1992; Sasano et al,
1992; Yuen et al, 2001). Whether these patterns of subcellular
localisation of c-Myc tend to reflect the malignant status of breast
cancer remains an enigma.
A recent study of the impact of DNA amplification on gene
expression patterns in breast cancer used mRNA and DNA from 14
breast cancer cell lines. Analysis was conducted with a 13000
cDNA clone array for gene expression measurement and a
Comparative Genomic Hybridisation (CGH) microarray for gene
copy number measurements. This study also included known
breast cancer genes, such as c-myc, HER/2-neu and aib1 (Hyman
et al, 2002). Interestingly, 44% of the most highly amplified genes
were also overexpressed at the mRNA level. Consistent with this
pattern, c-Myc gene copy number and its expression levels showed
a statistically significant (a¼0.020) correlation in this microarray
study of breast cancer cell lines. Another study, by Pollack and
colleagues, used microarray analysis and BAC array CGH of RNA
and DNA (respectively) extracted from intermediate grade human
breast tissues, and tested for amplification and expression of c-
Myc (among other genes). This study demonstrated that two out of
37 specimens were both amplified and overexpressed, while others
were either amplified or overexpressed, but not both. The authors
of this study suggested that contaminating stromal tissue may
compress the fluorescence ratios leading to underestimates of gene
amplification and overexpression (Pollack et al, 2002).
To more clearly address the importance of gene amplification
and expression of c-Myc in human breast cancer, we used in situ
methodologies, which can clearly distinguish stromal and carci-
noma components. We studied the amplification and over
expression of the c-myc gene with fluorescent in situ hybridisation
(FISH), non-radioactive in situ hybridisation (ISH) and immuno-
histochemical (IHC) approaches on paraffin-embedded biopsy
sections of untreated, high-grade breast cancer. It was observed
that 70, 92 and 70% of the cancer cases exhibited c-myc gene
amplification, its mRNA overexpression and its protein over
expression, respectively. In most of the cases (84%) that showed
gene amplification, the c-myc gene gained only one to two copies,
which is consistent with c-myc FISH data from other studies.
Unlike some oncogenes, such as N-myc, which typically demon-
strates gene amplification copy numbers of greater then 10 in
neuroblastoma, and HER-2/neu (Sartelet et al, 2002), whose copy
numbers range up to 14–40 in breast carcinomas (Isola et al,
1999), gene copy numbers of c-myc are not as greatly increased. In
the study noted earlier, using breast cancer cell line CGH array and
cDNA microarray expression analysis, it was demonstrated that
the most dramatically increased expression levels were associated
with large gene copy number increases, although low-level gains
and losses had a significant influence on gene expression
dysregulation (Hyman et al, 2002). Only one study has been
published (Pollack et al, 2002) that has begun to determine if these
findings are directly relevant to actual human breast tumour
tissues, since many of the genetic changes in tissue culture cell
lines are more extreme than those displayed in primary tumour
material. Furthermore, the relationships among gene amplifica-
tion, mRNA expression and c-Myc protein expression were not
explored in prior human breast cancer cell line and tumour tissue
studies (Hyman et al, 2002; Pollack et al, 2002).
In our human breast tumour tissue study, a high correlation was
found between c-myc FISH and ISH, for both percentage of
staining (Po0.0067) and intensity positive cells (Po0.0006). In
addition, c-myc gene copy amplification by FISH was correlated
with c-Myc protein expression positive cells by IHC (Po0.0016).
These results support the idea that c-Myc overexpression of both
mRNA and protein is related to the copy number of the c-myc
DNA amplification. We show in this study that amplification and
overexpression of c-Myc occur with high frequency in high-grade
human breast cancer tissues.
MATERIALS AND METHODS
Materials
Formalin-fixed, paraffin-embedded tissue blocks of breast carci-
noma and normal breast tissue were obtained from the
Histopathology and Tissue Shared Resource at the Lombardi
Comprehensive Cancer Center (LCCC), at Georgetown University
Medical Center. The criteria for tumour selection were the
following: negative progesterone receptor status, metastases to
auxiliary lymph nodes and high grade (Elston Score 47). The
oestrogen receptor status of the tumours was known from archived
pathology reports. The parameters were chosen from our prior
meta-analysis (Deming et al, 2000), as indications of a high
likelihood of c-myc gene amplification. Normal breast tissue
specimens were from reduction mammoplasty. Serial sections
(5mm) for FISH, ISH and IHC were prepared by the LCCC
Histopathology and Tissue Shared Resource.
FISH
A dual-label FISH technique was used (Jenkins et al, 1997). Slides
were baked overnight at 601C to assure adherence of the sample.
Tissue sections were deparaffinised with two successive, 10min
xylene washes, and then dehydrated in a graded ethanol series of
70, 80 and 95% at room temperature. Samples were then digested
with 4% pepsin (Sigma, St Louis, MO, USA) at 451C for 10min.
DNA probes used were an alpha satellite probe to chromosome 8,
labelled with biotin, and a c-myc probe, labelled with digoxigenin
(Ventana, Tucson, AZ, USA). Codenaturation was performed at
901 for 10min on a hot plate. Hybridisation was at 371C for 12–
16h. Detection of signals was accomplished with an antiavidin
antibody labelled with Texas Red, and an antidigoxigenin antibody
conjugated to fluorescein (Ventana, Tucson, AZ, USA). Slides were
postwashed in 2 SSC at 721C for 5min and counterstained with
DAPI to visualise cell nuclei. Results were viewed and quantified
with a Zeiss Axiophot fluorescence microscope, equipped with
appropriate filters and an Applied Imaging Cytovision system
(Pittsburgh, PA, USA). In this approach, the c-myc unique
sequence probe was visualised as a green signal and the control
probe for the chromosome 8 centromere was red, thus easily being
distinguished when scored.
One serial section from each tumour sample was stained with
haematoxylin and eosin and first reviewed by a pathologist (BS), to
help identify the tumour area of the section. This procedure
ensured that the tumour cells, but not the normal cells, were
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scounted. Nuclei of up to 50 tumour cells were scored from each
FISH-stained section, independently by two investigators. Hybri-
disation signals were averaged, and the amplification index was
presented as the number of c-myc signals divided by the number of
chromosome 8 centromere signals. A 1.8-fold increase was used as
the criterion to judge the presence of c-myc gene amplification.
In situ hybridisation
In situ hybridisation (ISH) was carried out with a nonradioactive
method, described previously (Liao et al, 2000a, b). One serial
section from each specimen was hybridised overnight at 601C with
riboprobes, that were in vitro transcribed from the antisense or
sense strand of an approximately 300bp cDNA of human c-myc
(ATCC, Manassas, VA, USA), labelled with digoxigenin-conjugated
UTP. The sections were then incubated with an antibody against
digoxigenin, followed by incubation with a second antibody
conjugated to alkaline phosphatase. The signal was visualised by
colour development with 5 bromo-4-chloro-3-indolyl phosphate
and nitroblue tetrazolium. All reagents were purchased from
Boehringer Mannheim, Indianapolis, IA. To control the signal
specificity, two serial sections were mounted on the same slide for
hybridisation with the antisense and sense probes, respectively.
ISH was given an intensity and percentage scores, based on
intensity of positive staining and number of cells staining,
respectively. Intensity scores were assigned 0, 1, 2 and 3, and
percentage scores were assigned as 1- 1–25, 2- 26–50, 3- 51–75
and 4- 76–100%.
Immunohistochemistry
Immunohistochemical staining (IHC) was performed using an
avidin–biotin complex (ABC) method described previously (Liao
et al, 1998). One serial section of each specimen was deparaffinised
and blocked with 3% peroxide. Antigens were retrieved by heating
slides in a microwave oven in 50mM citrate buffer, pH 6.4, at
boiling temperature, for 12min. After blocking with 6% normal
goat serum, the section was incubated with a mouse monoclonal
antibody to human c-Myc (9E10, Sigma Chemical Company, St
Louis, MO, USA) at 1:100 dilution for 2h, followed by 1h
incubation with a second antibody conjugated with biotin (Vector
Laboratories Inc., Burlingame, CA, USA). The section was then
incubated with peroxidase-conjugated avidin (Dako, Corporation,
Carpinteria, CA, USA) for 30min, followed by colour development
with diaminobenzidine and peroxide. All procedures were carried
out at room temperature. To control the signal specificity, serial
sections from 10 tumour samples were also stained using an
alternate c-Myc antibody (C19 from Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) at 1:60 dilution. This antibody resulted
in focally positive staining in the tumour, but the staining intensity
was weaker. To control the signal specificity, serial sections were
made from five selected positive cases which were subjected to the
same staining procedure, with a normal mouse IgG to replace the
c-Myc antibody. This control staining did not give rise to a signal,
demonstrating the specificity of the c-Myc antibody signal. IHC
staining was given an intensity and percentage score based upon
the intensity of positive staining and number of cells staining.
Intensity scores were assigned 0, 1, 2 and 3 and percentage scores
were assigned as 1- 1–25, 2- 26–50, 3- 51–75 and 4- 76–100%.
Determinations were made of cellular localisation of c-Myc
antibody staining to cytoplasm and/or nucleus in normal and
invasive cells within each breast tumour specimen.
Statistical analyses
For each analysis of gene copy amplification (FISH), mRNA
expression (ISH) and protein expression (IHC), all cases were first
grouped as positive or negative to calculate the percentages of
positive cases and negative cases, as described (Zar, 1974). Fisher’s
exact test was used to compare percentages, and two-sample t-test
or Wilcoxon rank test was used to compare average scores. Both
ISH and IHC were given intensity and percentage scores, based on
intensity of positive staining and number of cells staining,
respectively. As noted earlier, intensity scores were assigned 0, 1,
2 and 3 and percentage scores were assigned as 1- 1–25, 2- 26–50,
3- 51–75 and 4- 76–100%. A score of 42 for either intensity of
staining or percentage of cells positive by ISH was assigned as
high. For IHC, an intensity score of 41 was assigned as high and a
percentage score of 43 was categorised as high. Each amplifica-
tion index was paired with its corresponding mRNA expression
score to calculate the coefficient r. The same method was used to
estimate the association of the amplification indices with the c-
Myc protein expression levels, and the association of the mRNA
expression levels with the protein expression levels. A P-value of
0.05 or less was used to determine the statistical significance in all
analyses. In all, 54 pairs of normal vs invasive tissues were analysed
using McNemars w
2 test to determine if there was a difference in
cellular localisation of c-Myc antibody signal to nuclear or
cytoplasmic compartments.
RESULTS
FISH analysis of gene amplification
Amplification of the c-myc gene was measured by a FISH test in 46
cases of breast cancer; Figure 1 demonstrates cells with no
amplification (one copy of c-myc /one copy of chromosome 8
centromere, and a moderate amplification a 3/1 ratio). Amplifica-
tion was calculated by the number of c-myc signals divided by the
number of chromosome 8 alpha satellite signals. A 1.8-fold
increase cut-off was used to judge gene amplification. As shown
in Table 1, 32 out of 46 (70%) cases were gene amplified for c-myc,
whereas only 30% (14/46) of the cases showed amplification
indices lower than the cut-off value. The amplification indices for
most (84%, or 27/32) cases with gene amplification, ranged
between 1.8- and three-fold, indicating that the locus gained up to
two copies of c-myc in the majority of the cases. The percentage of
cases with gene gains of three copies or higher was 11% (five out of
46) of total cases analysed, or near 16% (five out of 32) of the cases
with gene amplification, including one case (2% of total cases or
3% of the cases with gene amplification) with the highest index of 5
(a gain of four copies).
In all, 28 of the breast carcinomas in this study were ER
negative, and 14 were ER positive. The average c-myc gene
amplification score was 1.896 (s.e.¼0.196) for ER positive and
2.201 (s.e.¼0.157) for ER negative. Although ER-negative tumours
had a slightly higher average c-myc score, the difference was not
statistically significant (two-sided P¼0.252 from two-sample t-test
and 0.251 from Wilcoxon rank test), consistent with the results of
our prior meta-analysis of the literature (Deming et al, 2000).
In situ hybridisation analysis of c-myc mRNA expression
A total of 51 breast cancer samples were studied for c-Myc mRNA
expression, with non radioactive in situ hybridisation (ISH). ISH
results were assigned intensity and percentage scores based upon
signal intensity of positive staining and number of cells staining
within the sample, respectively. As shown in Table 2, 86% (44 out
of 51) tumours were scored as high in intensity, and 92% (47out of
51) had more than 51% positive cells, also considered as highly
increased c-Myc expression. mRNA expression was heterogeneous
in the breast tumour tissue, and no morphologic subtype was
predominant in the high or low categories. One case showed no c-
Myc ISH staining. In 79% (38/48) of cases, epithelia in normal
mammary glands adjacent to the tumour also showed a high
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sintensity of staining. In three cases, no staining was seen in the
normal terminal duct lobular units. Figure 2 shows representative
fields of high, medium and low c-myc mRNA expression levels in
invasive ductal carcinoma samples.
Association of FISH and ISH
c-Myc scores were dichotomised as binary variables (high or low),
and a score of 2 or higher was categorised as high on ISH. A score
higher than median was categorised as high from FISH studies.
These dichotomised scores are depicted in Table 3. A Fisher’s exact
test was performed for comparing binary responses to see if there
was any association between FISH and ISH. It was found that the
FISH score was significantly associated with percentage of staining
in the invasive cells (P¼0.0067, two-sided McNemar’s test) and
also with the intensity score on ISH (P¼0.0006, two-sided).
Immunohistochemical staining of c-Myc proteins
In total, 51 breast carcinomas, which were subjected to FISH
analysis, and all of which also had been analysed for c-myc mRNA
by in situ hybridisation, were also analysed for the expression of c-
Myc protein, using immunohistochemical staining with the 9E10
antibody. IHC results were assigned an intensity and percentage
score based on intensity of positive staining and number of cells
staining, respectively. Intensity scores were assigned 0, 1, 2 and 3
and percentage scores were assigned as 0, 1- 0–25, 2- 26–50, 3-
51–75 and 4- 76–100. For IHC, an intensity score of 41 was
assigned as high and a percentage score of 43 was categorised as
high. Figure 2 shows examples of high, medium and low levels of c-
myc antibody staining in invasive ductal carcinoma samples. In 34
cases, normal tissue was seen; 30 of these showed cytoplasmic
staining and 22 had nuclear staining in terminal ductal lobular
units. In all, 12 cases showed 1þ, 14 cases 2þ and four cases 3þ
cytoplasmic staining. In situ hybridisation revealed positive
staining in 46 out of 49 cases with normal tissue. Seven cases
showed 1þ, 13 cases showed 2þ and 26 cases showed 3þ
staining by ISH. Both immunohistochemistry and in situ
hybridisation showed diffuse positivity in adipocytes.
Table 4 shows the staining pattern for the cohort. In all, 70% (36
out of 51) of cases showed high intensity of staining for c-Myc
protein, while 85% (29 out of 34) of cases with detectable staining
had more than 76% positive cells, also considered as high
expression. To verify the staining specificity, serial sections from
10 tumour specimens that were positive for 9E10 antibody were
also stained using the C19 rabbit polyclonal anti-c-Myc antibody.
Results revealed a staining pattern similar to 9E10. However, the
staining intensity with C19 was weaker than 9E10. The specificity
of these two antibodies was verified by Western blots in previous
studies (Persons et al, 1997; Liao et al, 2000b). Figure 2 shows
results of c-Myc in situ hybridisation and immunohistochemistry
studies on samples considered to demonstrate low, moderate and
high levels of c-Myc expression. Analysis of c-Myc protein
localisation results in the nucleus or cytoplasmic compartments
of normal and invasive cells within the tumours revealed that
nuclear staining was positive in 41% of normal cells, compared to
22% of invasive cells (statistical significance at P¼0.01 by
McNemar’s two-sided w
2 test). The increase in relative cytoplasmic
localisation of c-Myc protein, comparing normal (53.7%), to
invasive cells (61.1%) was not significantly different. Thus, the data
are consistent with partial exclusion of c-Myc from the nuclei of
invasive breast cancer cells.
The FISH score was significantly associated with the percentage
positivity of invasive cells, as seen on IHC studies of c-Myc.
However, 40% of tumours displayed a low index of c-myc gene
amplification, but still expressed high levels of c-Myc protein
(Table 6), indicating the possibility of other mechanisms of over
expression unrelated to gene amplification in at least some
tumours. The FISH score was not significantly associated with
the intensity of IHC staining in the invasive cells (not shown), in
contrast to the IHC percentage positivity score.
Figure 1 FISH analysis of c-myc amplification in tumour cells from breast tumour tissue sections. FISH probe for human c-myc unique-sequence is seen as
green, while the normal control signal, a centromeric probe signal for chromosome 8 is shown in red. The nuclei of tumour cells were visualised by DAPI
counter-staining. (A) 1:1 copy ratio of c-myc to chromosome 8 (c-myc/8 centromere), indicating no amplification of c-myc in tumour cells. (B) 1:3 copy
ratio of c-myc to chromosome 8 (c-myc/8 centromere), a moderate amplification of the c-myc gene.
Table 1 c-myc gene copy amplification analysis by FISH in poor
prognosis human breast tumour samples
Amplification index
(#c-myc signals/#
control signals)+
Percentage of samples with
FISH ratios in each category
1.0–1.7 30% 14 out of 46
1.8–1.99 20% Nine out of 46
2.0–2.9 39% 18 out of 46
43.0 11% Five out of 46
Analysis was conducted on 46 individual paraffin-embedded tissue samples with
negative progesterone receptor status, positive lymph node involvement and high
tumour grade. +Normal control ratio is 1.
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sDISCUSSION
Although there have been many reports on c-myc amplification in
human breast cancer (Liao and Dickson, 2000), there are only two
published studies involving application of the FISH technique to
unfixed, frozen sections (Persons et al, 1997; Visscher et al, 1997),
and one prior study using FISH on an archival human tissue
microarray (Schraml et al, 1999). Another recent study applied
FISH to evaluate c-myc amplification in ductal carcinoma in situ
(DCIS) (Aulmann et al, 2002). Using the FISH technique on
formalin-fixed, paraffin-embedded sections, we now show that
70% of high-grade breast cancer samples bear c-myc gene copy
amplifications. Interestingly, the above-mentioned study, using
FISH and focusing on DCIS, detected amplification of c-myc in
only 20% of cases, but found a correlation of c-myc with increased
tumour size and proliferation (Aulmann et al, 2002).
The level of amplification of c-myc in our study ranged between
one and four additional copies of the gene; the majority (84%) of
Table 2 c-myc mRNA in situ hybridisation (ISH) results
Staining intensity 0 1 2 3 Percent positivity 1 2 3 4
Number of tumour samples in each category N¼51 1 6 25 19 Number of tumour samples in each level category N¼51 1 3 5 42
In all, 51 human high-grade breast carcinomas were analysed to determine the relationships between c-Myc mRNA expression and c-myc gene in situ hybridisation results. Data
are shown in two ways in the above table. First, overall staining intensity of c-Myc-positive cells was scored as 0, 1, 2, 3 (low to high), and the number of tumour samples at each
level of staining indicated on the line below. Next, the percentage of tumour cells staining was scored as 0, 1, 2, 3, 4 (low to high %, as discussed in Materials and Methods). The
number of tumours at each level of percent cell positivity for c-Myc is then indicated on the line below.
Figure 2 Immunohistochemical staining and in situ hybridisation for c-Myc of three sets of invasive ductal carcinoma. (A, C and E) High (3þ),
intermediate (2þ) and low (1þ) level of staining by immunohistochemistry for c-Myc. (B, D and F) High (3þ), intermediate (2þ) and low (1þ) level of
staining by in situ hybridisation.
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sthe cases with the gene amplification gained only one to two
copies, also consistent with FISH data reported for c-myc copy
amplification in human metastatic prostate carcinoma tissues
(Jenkins et al, 1997). The relationship between the level of c-myc
gene copy amplification and the level its increased mRNA
expression has been examined previously in breast cancer cell
lines (Hyman et al, 2002). In general, it has been concluded that
the two scores coordinate for c-myc, as is the case for many breast
cancer genes. However, only 44% of the highly amplified genes, in
general, showed increased RNA expression, and only 10.5% of the
highly overexpressed genes were gene copy-amplified in the cell
line study (Hyman et al, 2002). Another analysis was conducted to
study of relationships between gene amplification and expression
of 6095 genes in 37 intermediate grade human breast tumours.
This study demonstrated that 62% of the highly amplified genes
also showed elevated expression; overall, a two-fold change in
DNA copy number was associated with a 1.5-fold change in mRNA
levels. Overall, 12% of the variation in gene expression in the
breast tumours studied was associated with gene copy number
variation (Pollack et al, 2002). Further study of additional human
breast tumours, at precisely defined grades and stages, will be
necessary in order to more fully define the relationships between
DNA copy numbers and expression of genes. The studies we report
here indicate higher levels of c-Myc gene amplification and
expression, than other previous reports in breast cancer. We
believe that this is probably the result of our analysis of individual
tumour cells in a well-defined set of high-grade breast tumours.
Prior c-Myc expression and amplification microarray studies used
tumour specimens which contain normal stromal components,
potentially underestimating amplification and expression levels of
the invasive tumour components (Pollack et al, 2002).
Our study reports a percentage of tumours gene amplified for c-
myc (using FISH in high-grade tumours) that is much higher than
the average figure (15.5%) reported in the literature (Isola et al,
2002). Most of the prior studies have employed the relatively
insensitive Southern blot technique, and were reviewed in a
recent meta-analysis (Deming et al, 2000). Consistent with this
prior literature background, a recent study of 94 lobular and
ductal breast cancers assessed amplification of c-myc by
using a semiquantitative PCR assay and protein expression, with
Table 3 Correlations between c-myc gene copy number (FISH) mRNA
expression (ISH)
FISH
Low High
(A) ISH (% cells)
Low 1 3
High 19 18
P¼0.0067
(B) ISH (intensity)
Low 25
High 18 16
P¼0.0006
Serial sections of high-grade human breast carcinomas were scored for c-myc gene
copy number (FISH, Table 1) and mRNA expression (ISH, Table 2). In (A), a positive
correlation (P¼0.0067) was observed between tumour samples with a high
percentage of cells demonstrating mRNA expression and a high c-myc gene copy
number. A score of 2 or higher was classified as high on ISH, and a score of median or
greater was categorised as high on FISH. In (B), a positive correlation (P¼0.0006)
was shown between a high level of intensity for c-Myc RNA expression a high and c-
myc gene copy number. Note that a pairwise comparison of FISH and ISH was not
possible for all cases, due to incomplete overlap of cases analysed with each assay.
Table 4 c-Myc immunohistochemistry (IHC) results
Staining intensity 0 1 2 3 Percent positivity 1 2 3 4
Number of tumour samples in each category 15 13 20 3 Number of tumour samples in each category 2 2 1 29
In all, 51 high-grade human breast carcinomas were analysed to determine the relationships between c-Myc protein expression and c-myc gene in situ hybridisation results. Data
are shown in two ways in the above table. First, overall staining intensity of c-Myc-positive cells was scored as 0, 1, 2, 3 (low to high), and the number of tumour samples at each
level of staining is indicated on the line below. Next, in a random subset of these cases, the percentage of tumour cells staining was scored as 0, 1, 2, 3, 4 (low to high %, as
discussed in Materials and methods). The number of tumours at each level of percent cell positivity for c-Myc is indicated on the line below.
Table 5 Nuclear/cytoplasmic localisation of c-Myc comparing normal
and invasive cells
Normal cells
(frequency percent)
Invasive cells
(frequency percent) Total
(A) Nuclear localisation
  +
  28 4 32
+1 4 8 2 2
Total 42 12 54
(B) Cytoplasmic localisation
  12 13 25
+ 9 20 21
Total 21 33 54
In all, 54 pairs (normal vs invasive) of tissues were analysed to answer the questions of
(1) whether positivity of nuclear cells in normal tissues is different from that in
invasive cells, and similarly (2) whether positivity of cytoplasmic cells in normal tissues
is different from that in invasive cells. The data are summarised in the above
contingency tables. In all, 22 normal cell specimens were positive for c-Myc staining
(40.71%), compared to 12 specimens (22.2%) in invasive cells. The difference is
statistically significant (P¼0.01) by McNemar’s w
2 test (two-sided).
Table 6 Correlation between c-Myc protein expression (IHC) and c-
myc gene copy number (FISH)
FISH
IHC (% cells) Low High
Low 3 0
High 10 15
P¼0.0016
Consecutive serial sections of high-grade human breast tumours were scored for c-
myc gene copy number or protein expression, by immunohistochemistry (IHC). IHC
scores were defined in the Materials and methods section. Data were analysed for
correlations between the results. A highly significant correlation was observed
between high c-Myc protein expression (IHC) between percent cells positive and
high c-myc gene amplification (FISH). P¼0.0016 from two-sided McNemar’s test.
Note that for 15 cases, no staining for c-Myc could be detected; these negative cases
were not included in the correlation presented, above.
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amplification in 21% of tumours (Jenkins et al, 1997), using assays
not based on in situ discrimination of tumour vs nontumour cells.
The lower frequency of c-myc in this prior study is in contrast with
the data we present here, and could be the result of the higher
sensitivity and precision of the FISH and immunohistochemical
methods, as distinct from quantitative PCR and Western blot
densitometry. In addition, the 70% of amplified tumours in our
study is also much higher than the 12% reported by Schraml et al
(1999), using a c-myc FISH test on a tissue microarray. This large
difference may be because the arrays are prepared from cores of
paraffin-embedded tissue, as small as 0.6mm in diameter which
may contain too few tumour cells for complete analysis of
amplification of a gene, such as c-myc.c - myc is known to be
quite heterogeneous in its gene amplification within individual
tumours (in contrast to HER2/neu, for example) (Persons et al,
1997).
Most previous reports on the expression of c-myc mRNA have
utilised Northern blot, dot blot or PCR-based approaches, while
just a few involved in situ hybridisation, which were primarily
performed on frozen tissue sections (Liao and Dickson, 2000).
Normal breast tissue is dominated by adipose cells, differing
greatly from tumour tissue in its epithelial cellularity. Thus,
normal and tumour tissues may not be rigorously compared by
techniques involving RNA extraction from total tissue. Therefore,
conclusions such as ‘increased expression’ may be more difficult to
make from studies with Northern blot, dot blot and PCR-based
techniques that require RNA extraction from tissues that have not
been fastidiously micro-dissected for selection of tumour cells.
Using a more sensitive, nonradioactive in situ hybridisation (ISH)
approach on formalin-fixed, paraffin-embedded sections, we
report herein high expression of c-myc mRNA in 92% of high-
grade breast carcinomas. This figure is much higher than the
recently reported data (22%), obtained by using a real-time RT–
PCR method (Bieche et al, 1999). Dilution of the RNA from
epithelium by the RNA from adipose in normal breast tissue in this
latest prior report may be one of the possible explanations for this
large difference.
In conclusion, the present study shows that approximately 70, 92
and 70% of biopsies of untreated high-grade breast cancer exhibit
c-myc gene amplification, mRNA overexpression and protein
overexpression, respectively. In most cases (84%), with gene copy
amplification, the c-myc gene gains one to two additional copies. c-
myc gene amplification was significantly associated with expres-
sion of its mRNA (both by intensity in invasive cells and by
percentage positivity in invasive cells), and with expression of its
protein (by percentage positivity in invasive cells). However, our
data were also consistent with the prior literature on c-Myc
(reviewed in Nass and Dickson, 1997; Liao and Dickson, 2000),
indicating complex transcriptional, post transcriptional, transla-
tional and post-translational control of c-Myc expression in vitro.
Specifically, in Table 5 we observed that in 40% of the high-grade
tumours tested, c-Myc protein was expressed at high levels, despite
a lack of its gene amplification.
It will be interesting to analyse lower grade tumours and
premalignant lesions, with the same measurement tools, to
determine if this c-myc amplification pattern is different,
comparing different steps in onset and progression of the
disease. Specifically, prior studies in fibroblasts and in human
mammary epithelial cells (Liao et al, 1998, 2000a, b) have
demonstrated that only a subtle deregulation of expression of c-
Myc is sufficient to allow genomic instability. These prior cell
biologic findings raise the question of whether c-Myc protein
expression precedes or follows its gene amplification during the
course of the natural history of breast cancer. It will also be
interesting for future studies of lower grade breast cancers and
premalignant lesions to determine whether there is evidence of
nuclear exclusion of c-Myc protein. Indeed, nuclear exclusion
of c-Myc in high-grade tumours could serve to attenuate its
functions in later stages of disease progression (Liao and Dickson,
2000).
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